ID   UT-OC-4
AC   CVCL_A1QY
SY   UT-OV-4
DR   Wikidata; Q105511654
RX   PubMed=9888470;
RX   PubMed=32487607;
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 14-08-25; Version: 5
//
RX   PubMed=9888470; DOI=10.1038/sj.bjc.6690046; PMCID=PMC2362186;
RA   Engblom, Pirjo R.
RA   Rantanen, Virpi
RA   Kulmala, Jarmo
RA   Helenius, Hans
RA   Grenman, Seija E.
RT   "Additive and supra-additive cytotoxicity of cisplatin-taxane
RT   combinations in ovarian carcinoma cell lines.";
RL   Br. J. Cancer 79:286-292(1999).
//
RX   PubMed=32487607; DOI=10.21873/anticanres.14294;
RA   Kuittinen, Tea I.
RA   Rovio, Paivi
RA   Luukkaala, Tiina H.
RA   Laurila, Marita
RA   Grenman, Seija E.
RA   Kallioniemi, Anne H.
RA   Maenpaa, Johanna U.
RT   "Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of ovarian
RT   cancer cells in vitro.";
RL   Anticancer Res. 40:3129-3138(2020).
//